Induction immunosuppression for combined heart–lung transplantation

Don Hayes, Patrick I. McConnell, Andrew R. Yates, Joseph D. Tobias, Mark Galantowicz, Heidi M. Mansour, Dmitry Tumin

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: Research on induction immunosuppression in patients undergoing combined heart–lung transplantation (HLTx) is limited. Methods: The United Network for Organ Sharing database was queried from 2000 to 2013 to examine the influence of induction immunosuppression for combined HLTx in adult (≥18 years) and adolescent (≥12 and <18 years) recipients. Results: Of 394 eligible combined HLTx cases (361 adults, 33 adolescents), 384 were included in univariate Cox analysis and 116 in the multivariate Cox model. Univariate analysis demonstrated no differences in survival by induction medication and no difference among the most common maintenance immunosuppression regimens. Adjusting for use of corticosteroids, multivariate analysis demonstrated no benefit of basiliximab (HR=3.582; 95% CI: 0.966, 13.279; P=.056), thymoglobulin/antilymphocyte globulin (ALG)/antithymocyte globulin (ATG) (HR=0.808; 95% CI: 0.134, 4.888; P=.817), alemtuzumab (HR=0.369; 95% CI: 0.087, 1.563; P=.176), or other induction medications (HR=1.511; 95% CI: 0.146, 15.610; P=.729), compared to no induction medication, with respect to mortality hazard post-HLTx. There were also no differences in treated acute rejection episodes by type of induction immunosuppression. Conclusions: Induction immunosuppression with contemporary agents does not improve survival after combined HLTx.

Original languageEnglish (US)
Pages (from-to)1332-1339
Number of pages8
JournalClinical Transplantation
Volume30
Issue number10
DOIs
StatePublished - Oct 1 2016

Keywords

  • adolescents
  • adults
  • heart and lung transplantation
  • immunosuppression
  • induction
  • survival

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Induction immunosuppression for combined heart–lung transplantation'. Together they form a unique fingerprint.

  • Cite this

    Hayes, D., McConnell, P. I., Yates, A. R., Tobias, J. D., Galantowicz, M., Mansour, H. M., & Tumin, D. (2016). Induction immunosuppression for combined heart–lung transplantation. Clinical Transplantation, 30(10), 1332-1339. https://doi.org/10.1111/ctr.12827